Medication Guide — Lifyorli 25 Mg

This Patient Information has been approved by the U.S. Food and Drug Administration.

Issued: 03/2026

LIFYORLI

(lif-YOR-lee)

(relacorilant)

capsules

LIFYORLI is a prescription medicine used with a chemotherapy medicine called nab-paclitaxel to treat adults with ovarian, fallopian tube, or primary peritoneal cancer who:

• have not responded to or are no longer responding to treatment with platinum-based chemotherapy, and
• have received one to three prior systemic treatments, at least one of which included bevacizumab.

It is not known if LIFYORLI is safe and effective in children.

are receiving or taking a steroid medicine by mouth or injection (systemic glucocorticoid) for lifesaving purposes. LIFYORLI can make glucocorticoid medicines less effective.

• plan to have surgery or have had surgery within the past 30 days
• have liver problems
• are pregnant or plan to become pregnant. LIFYORLI can harm your unborn baby.
  Females who are able to become pregnant:
  • Your healthcare provider should do a pregnancy test before you start treatment with LIFYORLI.
  • Use effective birth control (contraception) during treatment with LIFYORLI and for 1 week after your last dose. Talk with your healthcare provider about birth control methods you can use during this time.
  • Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with LIFYORLI.
  Males with female partners who are able to become pregnant:
  • Use effective birth control (contraception) during treatment with LIFYORLI and for 1 week after your last dose.
• are breastfeeding or plan to breastfeed. It is not known if LIFYORLI passes into your breast milk. Do not breastfeed during treatment with LIFYORLI and for 1 week after your last dose.

including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LIFYORLI with certain other medicines may affect how LIFYORLI or the other medicines work and may cause side effects.

See

Ask your healthcare provider if you are not sure if you take a glucocorticoid.

• Take LIFYORLI exactly as your healthcare provider tells you.
• Follow the LIFYORLI dosing instructions on the blister card.
• Take LIFYORLI 1 time on the day before, the day of, and the day after each nab-paclitaxel infusion.
• Take LIFYORLI with food.
• Swallow LIFYORLI capsules whole. Do not crush, chew, dissolve, or split the capsules
• If you miss a dose of LIFYORLI by less than 12 hours, take it as soon as you remember. If you miss a dose by more than 12 hours, skip the missed dose and take the next dose at your regular time. Do not take 2 doses at the same time to make up for a missed dose.
• If you vomit after taking LIFYORLI, do not take an extra dose.

What are the possible side effects of LIFYORLI?
LIFYORLI can cause serious side effects, including:

• low white blood cell count (neutropenia) and severe infections. LIFYORLI in combination with nab-paclitaxel can cause low white blood cell counts, which can lead to a fever and severe infections and cause death. Your healthcare provider will check your blood counts before each weekly treatment with LIFYORLI in combination with nab-paclitaxel and as needed. Tell your healthcare provider right away if you have a fever, chills, weakness, confusion, or other signs or symptoms of an infection.
• reduced effects of the hormone cortisol (adrenal insufficiency). LIFYORLI reduces the effect of an adrenal hormone called cortisol, which may be life-threatening and require hospitalization. This can happen at any time during treatment. Your risk of adrenal insufficiency is increased when your body is under stress, such as when you are sick, have an infection, or have surgery. Tell your healthcare provider right away if you develop the following symptoms during treatment with LIFYORLI:
  • feeling dizzy or lightheaded
  • low blood pressure (hypotension)
  • low blood sugar (hypoglycemia)
  • worsening weakness or tiredness
  • worsening nausea or vomiting
  • worsening loss of appetite or weight loss
• worsening of conditions treated with glucocorticoids. Treatment with LIFYORLI in people who also take glucocorticoids for other conditions may worsen symptoms of these conditions. LIFYORLI makes glucocorticoids less effective, and use of glucocorticoids makes LIFYORLI less effective. If you take a glucocorticoid medicine during treatment with LIFYORLI, tell your healthcare provider if symptoms of your other condition get worse.

:

• decreased red blood cell, white blood cell, and platelet counts
• tiredness
• nausea

• diarrhea
• rash
• decreased appetite

Your healthcare provider may change your dose of LIFYORLI, delay treatment, or completely stop treatment with LIFYORLI if you have certain side effects.

These are not all of the possible side effects of LIFYORLI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

• Store LIFYORLI at room temperature between 68°F to 77°F (20°C to 25°C).
• Store LIFYORLI in the original carton.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use LIFYORLI for a condition for which it was not prescribed. Do not give LIFYORLI to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about LIFYORLI that is written for health professionals.

: relacorilant

: butylated hydroxytoluene, lauroyl polyoxyl-32 glycerides, and propylene glycol caprylate. The 25mg capsule shell contains: black iron oxide, gelatin, red iron oxide, sorbitol special glycerin blend, titanium dioxide, and yellow iron oxide. The 100 mg capsule shell contains: gelatin, sorbitol special glycerin blend, titanium dioxide, and yellow iron oxide. The printing ink contains: ammonium hydroxide, black iron oxide, ethanol, ethyl acetate, isopropyl alcohol, macrogol/polyethylene glycol, polyvinyl acetate phthalate, propylene glycol, and purified water.

Manufactured for Corcept Therapeutics Incorporated, Redwood City, CA 94065

LIFYORLI

is a trademark of Corcept Therapeutics Incorporated.

Copyright 2026 Corcept Therapeutics Incorporated. All rights reserved.

PPI-220641-v01 03/2026

For more information, go to www.LIFYORLI.com or call 1-85-LIFYORLI (1-855-439-6754).